VPVishwajeet Puri

Vishwajeet Puri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vishwajeet Puri has a total of 92 co-authors. Here are the top co-authors by number of shared publications:

  • Mi-Jeong Lee

    Department of Human Nutrition, Food and Animal Sciences, University of Hawaii at Manoa, Honolulu, HI 96822, USA

    4 shared publications
  • Vishva M. Sharma

    Department of Biomedical Sciences and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH

    4 shared publications
  • Abhishek Gupta

    Department of Biomedical Sciences and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH

    3 shared publications
  • Bijinu Balakrishnan

    Department of Biomedical Sciences and Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH

    3 shared publications
  • Sukanta Jash

    Alpert Medical School of Brown University, Brown University, Providence, Rhode Island, USA

    3 shared publications
  • Jun Yin

    Section of Endocrinology, Diabetes, and Nutrition, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118

    2 shared publications

Latest Publications

  • Open Access

    Free Mitochondrial DNA and Mitophagy Dysfunction in Diabetic Kidney Disease: A Central Mitochondrial–Inflammatory Axis Driving Progressive Renal Injury

    by Aasthika Das, Eric Lalu, Vikky Awasthi, Cyrine Ben Dhaou, Hebaalaha Hussein, Glenn Gerhard, Karim Bahmed, Iris Lee, Vishwajeet Puri, Rihab Bouchareb

    Diabetic kidney disease (DKD) remains the leading cause of chronic kidney disease and end-stage renal failure worldwide despite significant advances in glucose-lowering and renoprotective therapies. Emerging evidence identifies mitochondrial dysfunction as a central pathogenic mechanism linking metabolic stress to chronic inflammation and progressive renal injury. In the diabetic kidney, hyperglycemia, lipotoxicity, and oxidative stress impair mitochondrial quality control pathways, particularly mitophagy, a targeted mitochondrial degradation pathway, leading to the accumulation of dysfunctional mitochondria and increased mitochondrial reactive oxygen species production. A critical consequence of mitochondrial damage is the cytosolic release of mitochondrial DNA (mtDNA), which acts as a potent damage-associated molecular pattern and can activate innate immune pathways, including cGAS–STING, NLRP3 inflammasome, and Toll-like receptor 9 signaling. Persistent mtDNA-driven immune activation promotes sterile inflammation, cellular senescence, extracellular matrix remodeling, and renal fibrosis, thereby establishing a vicious cycle that accelerates DKD progression. In this review, we examine the emerging role of the mitochondrial DNA–inflammatory axis in DKD, highlighting the interplay between mitophagy dysfunction, mtDNA release, innate immune activation, and fibrotic remodeling. We further discuss the potential of circulating and urinary mtDNA as biomarkers of disease activity and evaluate therapeutic strategies targeting mitochondrial quality control, oxidative stress, and mtDNA-sensing pathways. Collectively, these findings position mtDNA as a critical mechanistic link between mitochondrial dysfunction and chronic inflammation, and support targeting the mitochondrial–immune axis as a promising strategy for precision therapies in DKD.

  • Open Access

    Electronic Cigarette Exposure Induces Adverse Cellular Alterations in Skeletal Muscle in Male Mice Subjected to a High-Fat Diet

    by Juan Carlos Rivera, Jorge Espinoza-Derout, Kamrul Hasan, Candice J. Lao, Julian Wilson, Yin Tintut, Xuesi M. Shao, Maria C. Jordan, Kenneth P. Roos, Yanjun Liu, et al.

    Electronic cigarettes (E-Cig) are a new way of delivering nicotine, gaining popularity among adolescents and young adults, who often do not realize their harmful effects. Although the adverse effects of E-Cigs on the liver and heart have been demonstrated, their effects on the skeletal muscle have not been well studied. In this study, we evaluated the skeletal muscle effects of E-Cig aerosol, delivered in a manner similar to human vaping, in a mouse model of obesity induced by a high-fat diet (HFD). C57BL/6 mice, fed either a normal chow diet (NCD) or HFD, were exposed to either saline aerosol control or aerosol generated from Blu PLUSTM containing 0% or 2.4% nicotine for 12 weeks. Mice fed an NCD were included to distinguish whether E-Cig effects on the skeletal muscle required the presence of obesity induced by an HFD. The soleus muscle, an oxidative muscle rich in mitochondria, was assessed by Western blotting, electron microscopy, and biochemical assays. An NCD group was included to assess the baseline effects of HFD-induced obesity, on the skeletal muscle. The skeletal muscle from HFD-fed mice exposed to E-Cig 2.4% had reduced levels of phospho-AMPK compared with saline and E-Cig 0% groups, while E-Cigs had no effect on NCD-fed mice. Levels of phospho-adipose triglyceride lipase were also reduced in both E-Cig 2.4% and 0% compared with the saline group. These metabolic protein impairments were accompanied by increased levels of oxidative stress and phospho-p38 MAPK. Deregulation of the autophagy markers, microtubule-associated protein 1A/1B-light chain 3 (LC3-I; inactive form) and LC3-II (active form), was also observed, evidenced by decreased levels of LC3-II, ratio LC3-II/LC3-I, and increased levels of p62. Transmission electron microscopy analysis showed that E-Cig 2.4% induced damage to mitochondrial structure compared with the saline or E-Cig 0% groups. These findings suggest that E-Cig exposure on HFD impairs the skeletal muscle, adding to the growing list of affected organs for ongoing regulatory efforts concerning nicotine-containing substances.


  • Open Access

    Attenuation of high‐fat diet‐induced weight gain by apolipoprotein A4

    by Hsuan‐Chih N. Kuo, Zachary LaRussa, Flora Mengyang Xu, Leslie A. Consitt, Min Liu, W. Sean Davidson, Vishwajeet Puri, Karen T. Coschigano, Haifei Shi, Chunmin C. Lo

    Objective: Apolipoprotein A4 (APOA4) is synthesized by the small intestine in response to dietary lipids. Chronic exposure to a high‐fat diet (HFD) desensitizes lipid‐induced APOA4 production and attenuates brown adipose tissue (BAT) thermogenesis. We hypothesized that exogenous APOA4 could increase BAT thermogenesis and energy expenditure in HFD‐fed mice, resulting in decreased obesity and improved glucose tolerance.Methods: BAT and inguinal white adipose tissue (IWAT) thermogenesis, body composition, energy intake and expenditure, and locomotor activity were measured using an infrared camera, immunoblots, quantitative magnetic resonance imaging, and a comprehensive lab animal monitoring system. An intraperitoneal glucose tolerance test and hepatic lipid accumulation and steatosis were assayed.Results: Mice receiving continuous infusion of APOA4 for the last 4 weeks of 10 weeks of HFD feeding gained no additional body weight and had reduced fat mass but enhanced BAT and IWAT thermogenesis and energy expenditure, despite unaltered food intake and locomotor activity. Additionally, APOA4 infusion elevated fatty acid β oxidation; decreased lipogenesis, lipid accumulation, and steatosis in liver; and improved glucose tolerance.Conclusions: Maintenance of plasma APOA4 via exogenous APOA4 protein parallels elevation of BAT and IWAT thermogenesis, hepatic fatty acid β oxidation, and overall energy expenditure, with subsequent prevention of additional weight gain in HFD‐fed obese mice.


  • Endothelial-Specific Expression of CIDEC Protects From Age-Induced Skeletal Muscle Capillary Rarefaction and Declined Muscle Performance

    by Bijinu Balakrishnan, Chloe Becker, Kate Tenerowicz, Vishwajeet Puri

    We recently found that Cell death-inducing DNA fragmentation factor-a–like effector C (CIDEC), originally identified as lipid droplet-associated protein in adipocytes, is abundantly expressed in endothelial cells. We described its novel role in regulating vascular function in humans. To study the effect of endothelial-specific CIDEC in whole-body physiology and its molecular action in regulating vascular function, we generated a humanized mice model expressing endothelial-specific human CIDEC transgene (E-CIDECtg). E-CIDECtg mice showed protection against HFD-induced glucose intolerance and dyslipidemia. We also identified a molecular pathway of action whereby CIDEC directly regulates the VEGFA-VEGFR2 axis promoting eNOS signaling, angiogenesis, and vasodilation to improve metabolic health. Since aging and age-related declines in physical activity are associated with physical and metabolic impairment, and skeletal muscle capillarization is reduced in older adults, the objective of the present study was to evaluate the role of endothelial-specific CIDEC in the regulation of microvasculature remodeling in muscle, as well as muscle performance with aging. One-year to 14 months old E-CIDECtg mice (around 60 yrs human age) and their littermate controls were tested for muscle endurance and capillary density in the skeletal muscle. E-CIDECtg mice displayed enhanced muscle performance and higher capillary density in the skeletal muscle. Serum lipid parameters, LDL, triglycerides, fatty acids, and total cholesterol were lower, and the metabolic parameters including respiratory exchange ratio (muscle’s oxidative capacity), insulin tolerance and glucose tolerance were higher in aged E-CIDECtg mice. Overall, our study highlights endothelial-specific role of CIDEC in improving age-related decline in capillary density, muscle performance, and metabolic health. R01HL140836 and funds from Osteopathic Heritage Foundation's Vision 2020 to Heritage College of Osteopathic Medicine at Ohio University This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this Physiology was not involved in the peer review process.


  • Open Access

    Endothelial-Specific Expression of CIDEC Improves High-Fat Diet–Induced Vascular and Metabolic Dysfunction

    by Bijinu Balakrishnan, Abhishek Gupta, Rabia Basri, Vishva M. Sharma, Mark Slayton, Kailey Gentner, Chloe C. Becker, Shakun Karki, Harrison Muturi, Sonia M. Najjar, et al.

    Cell death-inducing DNA fragmentation factor-α–like effector C (CIDEC), originally identified to be a lipid droplet–associated protein in adipocytes, positively associates with insulin sensitivity. Recently, we discovered that it is expressed abundantly in human endothelial cells and regulates vascular function. The current study was designed to characterize the physiological effects and molecular actions of endothelial CIDEC in the control of vascular phenotype and whole-body glucose homeostasis. To achieve this, we generated a humanized mouse model expressing endothelial-specific human CIDEC (E-CIDECtg). E-CIDECtg mice exhibited protection against high-fat diet–induced glucose intolerance, insulin resistance, and dyslipidemia. Moreover, these mice displayed improved insulin signaling and endothelial nitric oxide synthase activation, enhanced endothelium-dependent vascular relaxation, and improved vascularization of adipose tissue, skeletal muscle, and heart. Mechanistically, we identified a novel interplay of CIDEC–vascular endothelial growth factor A (VEGFA)–vascular endothelial growth factor receptor 2 (VEGFR2) that reduced VEGFA and VEGFR2 degradation, thereby increasing VEGFR2 activation. Overall, our results demonstrate a protective role of endothelial CIDEC against obesity-induced metabolic and vascular dysfunction, in part, by modulation of VEGF signaling. These data suggest that CIDEC may be investigated as a potential future therapeutic target for mitigating obesity-related cardiometabolic disease.


  • Open Access

    Human CIDEC transgene improves lipid metabolism and protects against high-fat diet–induced glucose intolerance in mice

    by Abhishek Gupta, Bijinu Balakrishnan, Shakun Karki, Mark Slayton, Sukanta Jash, Sayani Banerjee, Tan Hooi Min Grahn, Srikarthika Jambunathan, Sarah Disney, Hebaallaha Hussein, et al.


  • Fsp27 plays a crucial role in muscle performance

    by Mark Slayton, Bijinu Balakrishnan, Abhishek Gupta, Scott Jobe, Ishika Puri, Savannah Neely, Yoshikazu Tamori, David W. Russ, Gozde Yildirim, Shoshana Yakar, et al.

    Fsp27 was previously identified as a lipid droplet-associated protein in adipocytes. Various studies have shown that it plays a role in the regulation of lipid homeostasis in adipose tissue and liver. However, its function in muscle, which also accumulate and metabolize fat, remains completely unknown. Our present study identifies a novel role of Fsp27 in muscle performance. Here, we demonstrate that Fsp27−/− and Fsp27+/− mice, both males and females, had severely impaired muscle endurance and exercise capacity compared with wild-type controls. Liver and muscle glycogen stores were similar among all groups fed or fasted, and before or after exercise. Reduced muscle performance in Fsp27−/− and Fsp27+/− mice was associated with severely decreased fat content in the muscle. Furthermore, results in heterozygous Fsp27+/− mice indicate that Fsp27 haploinsufficiency undermines muscle performance in both males and females. In summary, our physiological findings reveal that Fsp27 plays a critical role in muscular fat storage, muscle endurance, and muscle strength. NEW & NOTEWORTHY This is the first study identifying Fsp27 as a novel protein associated with muscle metabolism. The Fsp27-knockout model shows that Fsp27 plays a role in muscular-fat storage, muscle endurance, and muscle strength, which ultimately impacts limb movement. In addition, our study suggests a potential metabolic paradox in which FSP27-knockout mice presumed to be metabolically healthy based on glucose utilization and oxidative metabolism are unhealthy in terms of exercise capacity and muscular performance.


  • Lipid Composition of the Cell Membrane Outer Leaflet Regulates Endocytosis of Nanomaterials through Alterations in Scavenger Receptor Activity

    by Saeed Nazemidashtarjandi, Vishva M. Sharma, Vishwajeet Puri, Amir M. Farnoud, Monica M. Burdick

    Understanding the principles that guide the uptake of engineered nanomaterials (ENMs) by cells is of interest in biomedical and occupational health research. While evidence has started to accumulate on the role of membrane proteins in ENM uptake, the role of membrane lipid chemistry in regulating ENM endocytosis has remained largely unexplored. Here, we have addressed this issue by altering the plasma membrane lipid composition directly in live cells using a methyl-α-cyclodextrin (MαCD)-catalyzed lipid exchange method. Our observations, in an alveolar epithelial cell line and using silica nanoparticles, reveal that the lipid composition of the plasma membrane outer leaflet plays a significant role in ENM endocytosis and the intracellular fate of ENMs, by affecting nonspecific ENM diffusion into the cell, changing membrane fluidity, and altering the activity of scavenger receptors (SRs) involved in active endocytosis. These results have implications for understanding ENM uptake in different subsets of cells, depending on cell membrane lipid composition.


  • Open Access

    CIDEA Transcriptionally Regulates UCP1 for Britening and Thermogenesis in Human Fat Cells

    by Sukanta Jash, Sayani Banerjee, Mi-Jeong Lee, Stephen R. Farmer, Vishwajeet Puri


  • Open Access

    CIDE Proteins in Human Health and Disease

    by Mark Slayton, Abhishek Gupta, Bijinu Balakrishnan, Vishwajeet Puri

    Cell death-Inducing DNA Fragmentation Factor Alpha (DFFA)-like Effector (CIDE) proteins have emerged as lipid droplet-associated proteins that regulate fat metabolism. There are three members in the CIDE protein family—CIDEA, CIDEB, and CIDEC (also known as fat-specific protein 27 (FSP27)). CIDEA and FSP27 are primarily expressed in adipose tissue, while CIDEB is expressed in the liver. Originally, based upon their homology with DNA fragmentation factors, these proteins were identified as apoptotic proteins. However, recent studies have changed the perception of these proteins, redefining them as regulators of lipid droplet dynamics and fat metabolism, which contribute to a healthy metabolic phenotype in humans. Despite various studies in humans and gene-targeting studies in mice, the physiological roles of CIDE proteins remains elusive. This review will summarize the known physiological role and metabolic pathways regulated by the CIDE proteins in human health and disease.